HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opposite Sides Of GMP Coin: Contract Manufacturer, Own-Labeler Warned

This article was originally published in The Rose Sheet

Executive Summary

Contract manufacturer Nutritional Engineering was warned on Sept. 29, 2017, about GMP violations and misbranding problems found during an inspection in April and May. Liberty, Texas, own-labeler Carol Bond Health Foods was warned March 9 following a September inspection of its facility and a November review of its website.

You may also be interested in...

Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings

Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.

FDA Supplement GMP Crosshairs More Frequently On Smaller Firms

GMP violation warnings to three small dietary supplement firms in late March reflect a “thoughtful shift” by FDA toward inspections of smaller firms, says UNPA President Loren Israelsen. With the supplement GMP final rule past its 10-year anniversary, firms should be meeting their requirements.

Total Nutrition Latest Own-Label Supplement Marketer Warned On GMP Violations

FDA warns Total Nutrition that it violated numerous supplement GMPs and reminds the firm that own-label marketers are ultimately responsible for ensuring their contract manufacturers’ compliance. The agency also said numerous online claims rendered the products as unapproved drugs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts